MERCK & CO INC
Q3 2026 Form 13-F

KENILWORTH, NEW JERSEY
CIK 0000310158 · Publicly traded company
Consolidated report · includes 1 manager since Q4 2024
$820.3M Reported Value Total
Reported value
$820.3M
Quarter over quarter
+55.8%
Holdings
13
Top-10 concentration
99.9%

Filing Structure

Reports holdings for

  • MERCK SHARP & DOHME LLC (not a 13F filer in our records) · since Q4 2024

Key People

Directors & officers from Form 4 filings
Davis Robert M
Chairman, CEO & President
Deluca Richard R.
EVP&Pres, Merck Animal Heallth
Guindo Chirfi
EVP, Access, Policy & Comms
Zachary Jennifer
EVP, General Counsel
Maraldo David R.
EVP & Pres. MMD
Williams David Michael
EVP,Chief Info&Digital Officer

Description and Activity

Merck & Co., Inc. operates primarily in the pharmaceutical and animal health industries. In the pharmaceutical segment, Merck focuses on human health products and vaccines, offering prescription medications such as Keytruda for cancer, Gardasil for HPV prevention, ProQuad, and Januvia for diabetes. The animal health segment provides veterinary pharmaceuticals, vaccines, and health management solutions for both livestock and companion animals. These products are distributed to veterinarians, distributors, farmers, and pet owners.

Merck generates revenue through the sale of its pharmaceutical products and vaccines, with significant contributions from Keytruda, Gardasil, and other treatments. In 2024, pharmaceutical sales accounted for the majority of Merck's $64.17 billion in total sales, with animal health products also contributing to the revenue stream. The primary customers for Merck's products include wholesalers, retailers, hospitals, government agencies, managed health care providers, and individual consumers in the animal health market.

Merck's operational structure includes two main segments: Pharmaceuticals and Animal Health. The company's performance is directly impacted by competition from other pharmaceutical and animal health companies, regulatory pressures, and pricing controls in key markets. Patent protection is vital for its products, and the company relies on a diverse supplier base for raw materials. Additionally, legislative changes, such as those affecting drug pricing, can influence Merck's revenue and profit margins.

Company description summarized from 10-K filing.

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 13, 2026
Form 13F-HR
Reported value $820.3M
Positions 13
Change in reported value +55.8%
New positions 0
Exited positions 0
Position turnover 0.0%
Top-10 concentration 99.9%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
13 $820.3M
Q2 2026 13F
Filed Aug 7, 2026
13 $526.4M
Q1 2026 13F
Filed May 13, 2026
14 $349.4M
Q4 2025 13F
Filed Feb 17, 2026
12 $276.3M
Q3 2025 13F
Filed Nov 12, 2025
13 $228.0M
Q2 2025 13F
Filed Aug 13, 2025
13 $215.6M
Q1 2025 13F
Filed May 14, 2025
12 $164.3M
Q4 2024 13F
Filed Feb 14, 2025
13 $258.0M

Top 13 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 MRNA MODERNA INC $444.5M 54.18%
2 PSNL PERSONALIS INC $228.7M 27.87%
3 KYMR KYMERA THERAPEUTICS INC $86.3M 10.52%
4 AKTS AKTIS ONCOLOGY INC $18.6M 2.26%
5 EIKN EIKON THERAPEUTICS INC $13.4M 1.63%
6 TRDA ENTRADA THERAPEUTICS INC $11.0M 1.35%
7 ALEC ALECTOR INC $6.6M 0.8%
8 STRO SUTRO BIOPHARMA INC $4.4M 0.53%
9 EVAX EVAXION AS $4.0M 0.49%
10 VRDN VIRIDIAN THERAPEUTICS INC $1.9M 0.23%
11 XLOZZZZ XILIO THERAPEUTICS INC $959.1K 0.12%
12 HURA TUHURA BIOSCIENCES INC $40.8K < 0.01%
13 NEUP NEUPHORIA THERAPEUTICS INC $35.7K < 0.01%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings